Fangsheng Pharma to utilize RMB 100 million in idle funds

Hunan Fangsheng Pharmaceutical (SSE: 603998) announced plans to use up to RMB 100 million of its idle proprietary funds for cash management. Approved by the board, this strategy aims to enhance capital efficiency and increase returns without affecting the company's daily operations. The company will invest in low-risk, principal-protected financial products with terms of no more than 12 months, issued by commercial banks or securities firms. Risk mitigation measures include stringent counterparty selection, investment tracking, and internal auditing. The investment is expected to impact the company's balance sheet and income statement, particularly affecting items related to financial assets, cash, financial expenses, fair value changes, and investment income.